LivaNova (NASDAQ:LIVN) Given New $70.00 Price Target at Mizuho

LivaNova (NASDAQ:LIVN) had its price objective raised by equities research analysts at Mizuho from $65.00 to $70.00 in a research report issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price objective points to a potential upside of 23.63% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the stock. Barclays lifted their price target on shares of LivaNova from $55.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. The Goldman Sachs Group set a $55.00 target price on shares of LivaNova and gave the stock a “neutral” rating in a report on Wednesday, October 1st. Needham & Company LLC reiterated a “buy” rating and set a $64.00 target price on shares of LivaNova in a research report on Wednesday, September 3rd. Robert W. Baird increased their price target on LivaNova from $61.00 to $63.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LivaNova in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $62.43.

LivaNova Stock Performance

Shares of LivaNova stock opened at $56.62 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.29 and a quick ratio of 1.09. The firm has a 50 day simple moving average of $53.82 and a 200 day simple moving average of $48.68. LivaNova has a fifty-two week low of $32.48 and a fifty-two week high of $58.91. The firm has a market cap of $3.09 billion, a P/E ratio of -14.56 and a beta of 1.00.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.11 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.20. The firm had revenue of $357.80 million for the quarter, compared to analyst estimates of $342.32 million. LivaNova had a positive return on equity of 14.57% and a negative net margin of 16.13%.The business’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same period last year, the company earned $0.90 EPS. LivaNova has set its FY 2025 guidance at 3.800-3.90 EPS. Sell-side analysts predict that LivaNova will post 2.85 earnings per share for the current fiscal year.

Institutional Trading of LivaNova

A number of large investors have recently bought and sold shares of the business. Amundi grew its position in LivaNova by 7.2% in the first quarter. Amundi now owns 196,435 shares of the company’s stock valued at $7,362,000 after purchasing an additional 13,142 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in shares of LivaNova by 20.3% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 102,165 shares of the company’s stock worth $4,599,000 after buying an additional 17,252 shares during the last quarter. EP Wealth Advisors LLC bought a new position in shares of LivaNova in the 1st quarter valued at about $293,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of LivaNova in the second quarter valued at about $1,713,000. Finally, Hsbc Holdings PLC raised its holdings in LivaNova by 13.4% during the first quarter. Hsbc Holdings PLC now owns 6,666 shares of the company’s stock worth $258,000 after acquiring an additional 790 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.